Inhibition of IDH2 leads to an abnormal accumulation of ROS, likely due to suppression of the IDH2-mediated NADPH generation, and renders the cancer cells more vulnerable to ROS stress induced by cisplatin. This evidence concerns the gene IDH2 and cancer.